Show simple item record

dc.contributor.authorJordan, A
dc.date.accessioned2022-06-22T09:20:29Z
dc.date.issued2022-06-22
dc.date.updated2022-06-21T21:15:01Z
dc.description.abstractHypertension is a highly prevalent condition and, as a risk factor for vascular disease in particular, a leading contributory cause of death worldwide. Recent consensus guidelines suggest that moderate and severe (grade II and III) hypertension should be treated rapidly to achieve targets though, prior to the inception of this thesis, the evidence for the safety and efficacy of this approach, together with the physiological consequences of rapid hypertension treatment in moderate and severe disease, was limited. This thesis explores the clinical consequences of an 18-week treatment programme for individuals with grade II and III hypertension, using guideline- recommended pharmacological treatment, delivered over an accelerated timeframe. The blood pressure response to treatment is reported, together with the tolerance and safety of the protocol, as defined by the protocol completion rate, frequency of medication side effects and clinically significant adverse events. The programme also provided an opportunity to study health-rated quality of life in patients with moderate and severe hypertension and the effect of rapid treatment on health-related quality of life. This allowed for the first validation (according to modern standards) of an English language disease-specific instrument for measuring health-related quality of life in hypertension, following translation of the original MINICHAL disease-specific instrument from the original Spanish. In addition, the clinical treatment programme provided an opportunity to study the microvascular response to rapid treatment of moderate and severe hypertension, particularly with relevance to the rarefaction of hypertension and its reversal with treatment. Moreover, the morphological and functional myocardial consequences of treatment were determined, using cardiac MR imaging. Accordingly, this thesis presents evidence supporting the rapid treatment of moderate and severe hypertension, providing an opportunity for this to be studied in future investigations, with the aim of exploring whether this approach is prognostically advantageous for patients.en_GB
dc.identifier.urihttp://hdl.handle.net/10871/130009
dc.publisherUniversity of Exeteren_GB
dc.subjectHypertensionen_GB
dc.subjectProtocolen_GB
dc.subjectMicrocirculationen_GB
dc.subjectMRIen_GB
dc.subjectPROMsen_GB
dc.titleThe Characterisation and Treatment of Resistant Hypertensionen_GB
dc.typeThesis or dissertationen_GB
dc.date.available2022-06-22T09:20:29Z
dc.contributor.advisorShore, Angela
dc.contributor.advisorSharp, Andrew
dc.contributor.advisorSharp, Nick
dc.publisher.departmentCollege of Medicine and Health
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dc.type.degreetitleDoctor of Medicine
dc.type.qualificationlevelDoctoral
dc.type.qualificationnameDoctoral Thesis
rioxxterms.versionNAen_GB
rioxxterms.licenseref.startdate2022-06-22
rioxxterms.typeThesisen_GB
refterms.dateFOA2022-06-22T09:20:39Z


Files in this item

This item appears in the following Collection(s)

Show simple item record